Amino Collective

Amino Collective is a venture capital firm founded in 2020 and based in Berlin, Germany. Specializing in seed-stage investments, the firm focuses on health and biotechnology companies, aiming to support and advance innovative ideas in various sectors, including biology, health tech, digital health, life sciences, and synthetic biology. Amino Collective is dedicated to backing entrepreneurs and scientists, fostering collaboration, and facilitating the development of transformative health solutions.

Manuel Grossmann

Partner

Friedrich A. Neuman

Venture Partner

31 past transactions

Rematiq

Seed Round in 2025
Rematiq is a technology company specializing in AI-driven platforms for automating product compliance in the medical technology industry. Its software streamlines regulatory processes and manages product lifecycles, offering features such as impact and gap analysis, requirements management, regulatory intelligence, and change management. This enables medical innovators to efficiently navigate regulatory complexities throughout the product lifecycle.

Junction

Series A in 2025
Junction provides an open platform for real-time environmental monitoring and health data integration. It uses nine self-contained sensors to monitor building spaces and equipment, converting sensor data into actionable intelligence via cloud-based analytics. The platform integrates with other sensors and data sources to create refined insights.

ExpressionEdits

Seed Round in 2024
ExpressionEdits is a biotechnology company specializing in optimizing synthetic DNA instructions using AI-driven technology. It focuses on enhancing protein expression, a critical aspect of healthcare and biotech advancements.

Anima

Series A in 2024
Anima is a next-generation clinical operating system designed to enhance the efficiency of care teams in delivering optimal care plans to patients swiftly. The platform facilitates online consultations and offers a range of features, including comprehensive patient history management, one-click coding for record-keeping, and automated patient communications. It also incorporates limited assignment capabilities and patient access, along with integrated email and SMS messaging. Anima's advanced assignment and triage functionalities streamline workflows, while its full integration with electronic health records (EHR) ensures that notes are automatically generated, coded, and saved in the patient's record.

Biomia

Pre Seed Round in 2023
Biomia is a synthetic biology company focused on developing plant-derived natural products and novel small molecule therapeutics to treat central nervous system disorders, including pain, addiction, depression, and related neuropsychiatric and neurodegenerative conditions. It uses a drug discovery engine that combines machine learning, biosynthesis, and preclinical testing of nature-inspired molecules to identify safe and efficacious drug candidates and advance them through early development.

Lindus Health

Series A in 2023
Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Sensible Biotechnologies

Pre Seed Round in 2023
Sensible Biotechnologies is developing a cell-based design, optimization, and manufacturing platform to enable next-generation messenger RNA medicines. The platform integrates cell engineering, computational biology, and precision fermentation to create and manufacture high-quality mRNA constructs with reduced immunogenicity. In particular, it focuses on optimizing the production of vaccinia capping enzymes to improve the stability and translation of therapeutic mRNA, supporting the creation of vaccines and medicines that are more effective and accessible. The approach aims to streamline development from design to production, reducing time and cost in bringing mRNA therapies to patients.

Seqera

Series A in 2022
Seqera develops workflow orchestration software for life sciences research. Its open-source platform simplifies complex data analysis pipelines, enabling scientists to conduct research faster on larger datasets across multi-cloud environments.

Hedera Dx

Seed Round in 2022
Hedera Dx develops and commercializes liquid biopsy technology for hospital laboratories, enabling in-house clinically useful liquid biopsies that support tumor profiling and access to advanced diagnostic tools. The platform addresses regulatory compliance, privacy, and validation challenges and aims to simplify workflows that are currently inefficient. It offers early detection, therapy selection, and recurrence monitoring capabilities alongside aggregated clinical insights to help clinicians and researchers reduce cancer-related mortality and improve patient outcomes, while supporting drug development. Hedera Dx was founded on July 1, 2021 in Epalinges, Vaud.

Kernal Biologics

Series A in 2022
Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

Aware

Seed Round in 2022
Aware is a mobile health app that helps users evaluate their health data and study chronic diseases. It enables individuals to understand what is happening inside their body and how data can be used to manage wellbeing. The offering includes blood tests through a subscription model and provides research services related to chronic diseases, delivering insights that aim to help clients understand their internal health and take informed steps to improve their health outcomes.

Junction

Seed Round in 2022
Junction provides an open platform for real-time environmental monitoring and health data integration. It uses nine self-contained sensors to monitor building spaces and equipment, converting sensor data into actionable intelligence via cloud-based analytics. The platform integrates with other sensors and data sources to create refined insights.

Kano Therapeutics

Pre Seed Round in 2022
Kano Therapeutics is a biotechnology company dedicated to advancing genome-editing therapies through innovative biomaterials. The company specializes in the correction of gene-length DNA using circular single-stranded DNA biomaterials, providing a comprehensive platform that integrates manufacturing, application, and computational tools for genetic payload development. By leveraging DNA nanotechnology and synthetic biology, Kano Therapeutics designs and engineers novel gene vectors that effectively carry genetic information. This enables researchers and pharmaceutical companies to enhance gene delivery methods and develop vaccine constructs, ultimately supporting the progression of genetic cures in a safe and efficient manner.

Vira Health

Series A in 2022
Vira Health is a digital health company focused on improving long-term health for women by addressing female-specific conditions and advancing the collection and use of female health data. It develops a digital platform and mobile app that provides personalized care for women going through menopause, combining exercise programs, diet guidance, and cognitive behavioral therapy to help manage menopausal symptoms and enhance overall well-being and quality of life.

Nostos Genomics

Seed Round in 2022
Nostos Genomics partners with genetic testing labs to accelerate diagnoses for individuals with genetic diseases. Their platform combines machine learning and synthetic biology to enhance diagnostic accuracy and efficiency.

Kenbi

Series A in 2021
Kenbi is a nurse-centric outpatient care company focused on enhancing the delivery of healthcare services. It provides outpatient care management aimed at supporting nurses and addressing gaps in the healthcare system. By leveraging technology, collegial organizational structures, and human-centric design, Kenbi organizes local care teams to deliver a range of outpatient and at-home services. These services include medical care covered by insurance, as well as household assistance, guidance, and companionship for patients. The company's approach is designed to reduce the time healthcare practitioners spend on bureaucratic tasks, allowing them to focus more on patient care and improving the overall experience for patients and their families.

Aware

Seed Round in 2021
Aware is a mobile health app that helps users evaluate their health data and study chronic diseases. It enables individuals to understand what is happening inside their body and how data can be used to manage wellbeing. The offering includes blood tests through a subscription model and provides research services related to chronic diseases, delivering insights that aim to help clients understand their internal health and take informed steps to improve their health outcomes.

Lindus Health

Seed Round in 2021
Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Seqera

Seed Round in 2021
Seqera develops workflow orchestration software for life sciences research. Its open-source platform simplifies complex data analysis pipelines, enabling scientists to conduct research faster on larger datasets across multi-cloud environments.

Vira Health

Seed Round in 2021
Vira Health is a digital health company focused on improving long-term health for women by addressing female-specific conditions and advancing the collection and use of female health data. It develops a digital platform and mobile app that provides personalized care for women going through menopause, combining exercise programs, diet guidance, and cognitive behavioral therapy to help manage menopausal symptoms and enhance overall well-being and quality of life.

NuvoAir

Series A in 2021
NuvoAir is a healthcare technology company that offers a value-based specialty care platform and remote monitoring tools for chronic heart and lung conditions. Founded in 2015 and based in Stockholm, Sweden, it develops home respiratory monitoring and analytics delivered by a multidisciplinary team of pulmonologists and cardiologists. The platform enables proactive virtual care and partners with health plans and risk-bearing entities under flexible, value-based payment arrangements to improve patient outcomes and reduce healthcare costs by enabling early detection of deterioration and personalized management.

Anima

Seed Round in 2021
Anima is a next-generation clinical operating system designed to enhance the efficiency of care teams in delivering optimal care plans to patients swiftly. The platform facilitates online consultations and offers a range of features, including comprehensive patient history management, one-click coding for record-keeping, and automated patient communications. It also incorporates limited assignment capabilities and patient access, along with integrated email and SMS messaging. Anima's advanced assignment and triage functionalities streamline workflows, while its full integration with electronic health records (EHR) ensures that notes are automatically generated, coded, and saved in the patient's record.

Anima

Pre Seed Round in 2021
Anima is a next-generation clinical operating system designed to enhance the efficiency of care teams in delivering optimal care plans to patients swiftly. The platform facilitates online consultations and offers a range of features, including comprehensive patient history management, one-click coding for record-keeping, and automated patient communications. It also incorporates limited assignment capabilities and patient access, along with integrated email and SMS messaging. Anima's advanced assignment and triage functionalities streamline workflows, while its full integration with electronic health records (EHR) ensures that notes are automatically generated, coded, and saved in the patient's record.

Kenbi

Seed Round in 2021
Kenbi is a nurse-centric outpatient care company focused on enhancing the delivery of healthcare services. It provides outpatient care management aimed at supporting nurses and addressing gaps in the healthcare system. By leveraging technology, collegial organizational structures, and human-centric design, Kenbi organizes local care teams to deliver a range of outpatient and at-home services. These services include medical care covered by insurance, as well as household assistance, guidance, and companionship for patients. The company's approach is designed to reduce the time healthcare practitioners spend on bureaucratic tasks, allowing them to focus more on patient care and improving the overall experience for patients and their families.

Awell

Seed Round in 2020
Awell Health is a healthcare technology company focused on improving patient outcomes through the creation and implementation of care pathways. The company offers a cloud-based platform that integrates with existing clinical workflows, allowing healthcare organizations to automate routine clinical tasks and synchronize data across various systems. By facilitating seamless coordination between care teams and patients, Awell Health empowers physicians and care teams to make informed decisions at each stage of the patient care journey. Recognizing that the healthcare sector often relies on disjointed and outdated processes, Awell Health aims to reorganize these workflows, moving beyond mere data collection to enhance the overall efficiency and effectiveness of care delivery.

Allcyte

Seed Round in 2020
Allcyte is a biotech start-up specializing in functional drug testing using primary human materials. The company has developed a high-content imaging platform known as Pharmacoscopy, which incorporates AI-supported image analysis to assess drug effects at the single-cell level. This technology closely simulates in vivo conditions, allowing for a realistic preview of drug efficacy in actual patients. Allcyte's mission is to advance personalized medicine for cancer treatment by providing physicians and pharmaceutical companies with critical insights to prioritize the most suitable drugs for specific indications. By minimizing sample manipulation and employing sophisticated statistical and machine learning techniques, Allcyte aims to enhance biomedical decision-making and optimize cancer treatment outcomes.

Nostos Genomics

Pre Seed Round in 2020
Nostos Genomics partners with genetic testing labs to accelerate diagnoses for individuals with genetic diseases. Their platform combines machine learning and synthetic biology to enhance diagnostic accuracy and efficiency.

Seqera

Seqera develops workflow orchestration software for life sciences research. Its open-source platform simplifies complex data analysis pipelines, enabling scientists to conduct research faster on larger datasets across multi-cloud environments.

Hedera Dx

Hedera Dx develops and commercializes liquid biopsy technology for hospital laboratories, enabling in-house clinically useful liquid biopsies that support tumor profiling and access to advanced diagnostic tools. The platform addresses regulatory compliance, privacy, and validation challenges and aims to simplify workflows that are currently inefficient. It offers early detection, therapy selection, and recurrence monitoring capabilities alongside aggregated clinical insights to help clinicians and researchers reduce cancer-related mortality and improve patient outcomes, while supporting drug development. Hedera Dx was founded on July 1, 2021 in Epalinges, Vaud.

Inductive Bio

Inductive Bio develops a machine learning platform that accelerates compound optimization for pharmaceutical research. It focuses on building datasets and ML models to predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of small molecules, enabling scientists to optimize initial compounds into leads and development candidates more efficiently.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.